Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fujisawa Yukio is active.

Publication


Featured researches published by Fujisawa Yukio.


Gene | 1985

Expression of hepatitis B virus surface antigen P31 gene in Escherichia coli

Fujisawa Yukio; Ito Vasuaki; Ikeyama Shuichi; Kikuchi Masakazu

A hepatitis B virus surface antigen (HBsAg) P31-coding DNA was constructed from a DNA fragment of the plasmid pHBr330 containing the entire hepatitis B virus (HBV) adr DNA and a chemically synthesized adaptor. The P31 gene was inserted into an expression vector, pTRP771, having an Escherichia coli tryptophan operon (trp) promoter to give a recombinant plasmid pTRP P31-R. The distance between the Shine-Dalgarno (SD) sequence and the initiation codon of P31 gene was adjusted to 9 bp. The expression level of HBsAg by E. coli 294[pTRP P31-R] was significantly elevated, in contrast to that of HBsAg by E. coli 294[pTRP SS-6]. Western blotting analysis has shown that E. coli[pTRP P31-R] synthesizes a specific polypeptide P31 of about 31 kDal, which reacts with anti-HBsAg antibody. The binding studies with polyalbumins from various species have also suggested that HBsAg P31 specifically binds to polymerized human serum albumin.


Gene | 1989

Efficient expression of genetically engineered hepatitis B virus surface antigen P31 proteins in yeast

Kuroda Shunichi; Itoh Yasuaki; Miyazaki Takeshi; Otaka-Imai Sachiko; Fujisawa Yukio

Abstract We have constructed plasmids that express modified hepatitis B virus surface antigen (HBsAg) P31-coding genes ( M-P31c, d, e, f, and i having various genetically engineered pre-S2 regions. The plasmids contain the GAPDH (gene coding for glyceraldehyde-3-phosphate dehydrogenase) promoter and the PGK (gene coding for 3-phosphoglycerate kinase) terminator, both isolated from sake brewing yeast, Saccharomyces cerevisiae Kyokai III. Expression levels of the modified HBsAg P31 proteins in yeast are greatly increased from 0.4% to 11.7% of total cell protein. However, the specific mRNAs are expressed at equal levels and the degradation rates of the modified P31 proteins do not vary significantly. Therefore, we considered that different expression levels of the modified P31 proteins are attributed to the changes of the post-translational efficiency. And it was suggested that the conformational stability of the N-terminal peptide (Met-l-Phe-46) in the endoplasmic reticulum membrane determines the expression level of modified P31 proteins.


Archive | 1996

ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN L INHIBITALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN L INHIBITOR OR

Sohda Takashi; Fujisawa Yukio; Yasuma Tsuneo; Mizoguchi Junji


Archive | 1994

Alcohol or aldehyde derivative and its use

Soda Takashi; Fujisawa Yukio; Yasuma Tsuneo; Mizoguchi Junji; Kori Masaki; Takizawa Masayuki


Archive | 1990

Modified hepatitis B virus surface antigen P31 and production thereof

Fujisawa Yukio; Itoh Yasuaki; Nishimura Osamu; Fujii Tomoko


Archive | 1996

LACTOL DERIVATIVE, ITS PRODUCTION AND USE

Soda Takashi; Fujisawa Yukio; Oi Satoru; Mizoguchi Junji


Archive | 1997

MEDICINE FOR ENHANCING ACTION OF CELL DIFFERENTIATION-INDUCTING FACTOR

Fujisawa Yukio; Hasama Masaaki; Iwagami Norihisa


Archive | 1996

CATHEPSIN L INHIBITOR

Soda Takashi; Fujisawa Yukio; Yasuma Tsuneo; Mizoguchi Junji


Archive | 1994

HUMAN ANGIOTENSIN II TYPE 1 RECEPTOR, ITS PRODUCTION AND USE

Fujisawa Yukio; Kuroda Shunichi; Konishi Hiroaki


Archive | 1992

PRODUCTION OF VIRUS PROTEIN BY SCHIZOSACCHAROMYCES POMBE

Fujisawa Yukio; Hinuma Kuniji; Otaka Sachiko

Collaboration


Dive into the Fujisawa Yukio's collaboration.

Top Co-Authors

Avatar

Mizoguchi Junji

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Sohda Takashi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kikuchi Masakazu

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Nishimura Osamu

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Ikeyama Shuichi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Fujii Tomoko

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Itoh Yasuaki

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Konishi Hiroaki

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kuroda Shunichi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Kanzaki Toshihiko

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge